What is Epigenetics?

Epigenetics, is a branch of genetics that studies the “epigenetic” changes in cancer, in other words, it studies the changes that affect the gene sequence without altering its structure, but it does modify the expression of genes, this is important because the epigenetic ambient can be capable of blocking or inhibiting the expression of the tumor-suppressing genes, or the genes control tumors.

We approach this as an important part of the comprehensive treatment of patients with cancer that receive immune cell therapy, by combining the therapeutic strategy that favors the release of the genes that suppress tumors, this helps controlling and remission of tumors in a most effective way.

There are several products currently evaluated and approved for the epigenetic treatment, DNA methyltransferase (DNMT)blockers like procaine, which have shown that they can revert the aberrant mutations of DNA and  are associated with the occurrence of tumors, such as breast, liver, lung and nasopharyngeal cancer.

We also studied the effect when combined with certain cytotoxic agents such as cisplatin that demonstrated an increased therapeutic rate, and improved antitumor activity.

Immune System Activation

Recent studies indicate that immunotherapy is among the most promising strategies of modern cancer therapy. Its aim is to strengthen the innate and acquired immunity, highly specific for tumor cells and low toxicity to healthy cells of the patient.   Cellular immunotherapy is being considered as the fourth line of conventional therapy for cancer patients, since it has demonstrated in certain patient groups that it is effective in delaying the progression, improving quality of life, and in some cases, to lower tumor lesions.

• – We evaluated the cellular immunotherapy in patients with various solid tumors, since the person’s immune system has the same components and the same activation pathways, therefore all patients, and not the tumors, should respond similarly to activation of the immune system, the difference between the various types of (tumors) neoplasms, are the proteins that they release, the inaccessible vascular sites where they are located, and the blocking conditions and systemic toxicity that each patient has individually; as we reviewed earlier, the improvement of these conditions, leaves  the immune response  ready, unobstructed, to be activated effectively and efficiently.
• – Each individual will respond differently to the activation of the immune system, these differences are essentially quantitative, namely that some patients produce a larger amount of interferon and interleukins, for example; while other patients produce less of these proteins and cytokines. This principle is that the results cannot be homogenized or similar between patients, the immune response will depend on these conditions, but we have observed that even patients that produce low amounts of these activating proteins, will develop an effective immune response. Each individual will respond differently to the activation of the immune system, these differences are essentially quantitative, namely that some patients produce a larger amount of interferon and interleukins, for example; while other patients produce less of these proteins and cytokines. This principle is that the results cannot be homogenized or similar between patients, the immune response will depend on these conditions, but we have observed that even patients that produce low amounts of these activating proteins, will develop an effective immune response.

– Our goal is to improve the general conditions of patients, improve the quality of life so that it will be reflected in the survival, equally a remission or the disease stability and the delay in progression of the same, are other our goals, for these reasons the results will be independent of each patient and the immune response depends on the patient’s own immune system.